Market revenue in 2023 | USD 303.1 million |
Market revenue in 2030 | USD 442.5 million |
Growth rate | 5.6% (CAGR from 2023 to 2030) |
Largest segment | Molecular diagnostics |
Fastest growing segment | Immunoassays |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoassays, Hematology and Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy |
Key market players worldwide | Quest Diagnostics Inc, 23andMe Holding Co Class A, Abbott Laboratories, Guardant Health Inc, NeoGenomics, Siemens Healthineers AG ADR, Qiagen NV, Illumina Inc, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to laboratory developed tests market will help companies and investors design strategic landscapes.
Molecular diagnostics was the largest segment with a revenue share of 23.46% in 2023. Horizon Databook has segmented the Brazil laboratory developed tests market based on immunoassays, hematology and coagulation, molecular diagnostics, microbiology, clinical chemistry, histology/cytology, flow cytometry, mass spectroscopy covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of chronic diseases is high in the country due to the moderate standards of living, which increases the need for advanced diagnostic and treatment options. It has been found that infectious diseases are a major cause of death in Brazil. Hence, public and private organizations are undertaking initiatives to reduce the mortality rate.
For instance, in October 2018, Dasa entered into a partnership with Karius, Inc. to introduce Karius's next-generation sequencing-based infectious disease tests in Brazil. The technology will be available to multiple hospitals in the country to provide quick and accurate results. Several developments in the country would impact the Laboratory-Developed Tests (LDTs) market positively.
In addition, the developing biotechnology sector in Brazil is a key driving force for this market. Supportive government initiatives, such as the collaboration between the U.S. and Brazil on biomedical research to accelerate R&D on the diagnosis & treatment of infectious diseases, also drives the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil laboratory developed tests market , including forecasts for subscribers. This country databook contains high-level insights into Brazil laboratory developed tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account